Delayed Commercialization And Slow Consumables Adoption Will Eventually Support Long-Term Proteomics Potential

AnalystLowTarget

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

09 Dec 25

Updated

26 Jun 26

Views

Not Invested

Shared on 26 Jun 26

Fair value Decreased 50%

QSI: Partnership Progress Will Support Future Single Molecule Sequencing Adoption

Quantum-Si teams up with Cell Signaling Technology to sharpen how its Proteus system spots key protein changes, and plans head-to-head checks against another widely used lab method to prove it works. The company also reports progress toward a more automated workflow, even as expectations for what the business is worth and how fast it must grow get reset.

6 views

Fair Value vs Share Price

US$1

vs US$0.7624.4% undervalued

138.2%

Revenue growth

15.6%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Quantum-Si

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with low risk.

Market capUS$166.7m

PB0.8x

Estimated Growth63.8%

Dividend YieldN/A

Full analysis

CEO & management

Jeffrey Hawkins

CEO

3.5yrs

CEO Tenure

A life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS).